ARYx Therapeutics, Inc. (ARYX)

ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of product candidates to eliminate known safety issues associated with commercial drugs. It uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of these original drugs and are metabolized to avoid specific adverse side effects associated with these compounds. The company has three products in Phase 2 clinical trials: ATI-7505 for the treatment of various gastrointestinal disorders, ATI-5923 for the treatment of patients at risk for the formation of dangerous blood clots, and ATI-2042 for the treatment of atrial fibrillation. It also has multiple product candidates in preclinical development, including ATI-9242 for the treatment of schizophrenia and other psychiatric disorders. The company has collaboration agreement with Procter & Gamble Pharmaceuticals, Inc. for the development and commercialization of ATI-7505. ARYx Therapeutics was incorporated in 1997 and is based in Fremont, California.